Article Text

FRI0470 Comparative Study of Infliximab versus Adalimumab in Patients with Refractory Uveitis Due to BehÇEt's Disease. Multicenter Study of 125 Cases
  1. E. Beltrán-Catalán1,
  2. V. Calvo-Río2,
  3. P. Rodríguez-Cundin2,
  4. R. Blanco-Alonso2,
  5. J. Sánchez-Bursόn3,
  6. M. Mesquida4,
  7. A. Adán4,
  8. M.V. Hernandez5,
  9. M. Hernandez Garfella6,
  10. L. Martínez-Costa7,
  11. A. Sellas8,
  12. M. Cordero Coma9,
  13. M. Díaz-Llopis10,
  14. J.L. García Serrano11,
  15. N. Ortego12,
  16. J.M. Herreras13,
  17. A. Fonollosa14,
  18. Ά.M. García-Aparicio15,
  19. O. Maíz16,
  20. A. Blanco17,
  21. I. Torre18,
  22. C. Fernández-Espartero19,
  23. V. Jovaní20,
  24. D. Peiteado21,
  25. E. Pato-Cour22,
  26. J. Cruz23,
  27. E. Aurrecoechea24,
  28. M. García25,
  29. M.A. Caracuel26,
  30. C. Montilla27,
  31. A. Atanes28,
  32. F. Francisco29,
  33. S. González30,
  34. M.A. González-Gay2
  35. on behalf of Study Group: Elia Valls, Roberto Gallego, Carlos Fernández, Amalia Sánchez, Fernando Gamero, Luis Linares, Javier García, Raquel Almodovar, Enrique Minguez, Carmen Carrasco, Alejandro Olive, Julio Vázquez, Oscar Ruiz, Javier Manero, Natalia Palmou, Santiago Muñoz-Fdez
  1. 1Servicio de Reumatología, Hospital General Universitario, Valencia
  2. 2Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander
  3. 3Servicio de Reumatología, Hospital de Valme, Sevilla
  4. 4Servicio de Oftalmología
  5. 5Servicio de Reumatología, Hospital Clínic, Barcelona
  6. 6Servicio de Oftalmología, Hospital General Universitario
  7. 7Servicio de Oftalmología, Hospital Dr.Peset, Valencia
  8. 8Servicio de Reumatología, Hospital Vall d'Hebrόn, Barcelona
  9. 9Servicio de Oftalmología, Hospital de Leόn, Leόn
  10. 10Servicio de Oftalmología, Hospital la Fe, Valencia
  11. 11Servicio de Oftalmología
  12. 12Unidad de Enfermedades Autoinmunes, Hospital San Cecilio, Granada
  13. 13Servicio de Oftalmología, Hospital Universitario IOBA, Valladolid
  14. 14Servicio de Oftalmología, Hospital de Cruces, Bilbao
  15. 15Servicio de Reumatología, Hospital de Toledo, Toledo
  16. 16Servicio de Reumatología
  17. 17Servicio de Oftalmología, Hospital Donosti, San Sebastian
  18. 18Servicio de Reumatología, Hospital Basurto, Bilbao
  19. 19Servicio de Reumatología, Hospital Universitario de Mόstoles, Madrid
  20. 20Servicio de Reumatología, Hospital General Universitario, Alicante
  21. 21Servicio de Reumatología, Hospital Universitario La Paz
  22. 22Servicio de Reumatología, Hospital Universitario Clínico San Carlos, Madrid
  23. 23Servicio de Reumatología, Hospital de Pontevedra, Pontevedra
  24. 24Servicio de Reumatología, Hospital Sierrallana, Torrelavega
  25. 25Servicio de Reumatología, Hospital La Princesa, Madrid
  26. 26Servicio de Reumatología, Hospital de Cόrdoba, Cόrdoba
  27. 27Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca
  28. 28Servicio de Reumatología, Complexo Hospitalario Universitario, A Coruña
  29. 29Servicio de Reumatología, Hospital Dr. Negrín, Canarias
  30. 30Servicio de Reumatología, Hospital Cabueñes, Gijόn, Spain


Objectives To compare the efficacy and safety of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year period.

Methods Multicenter study of 125 patients with BD's uveitis refractory to conventional treatment including high-dose corticosteroids and at least one standard immunosuppressive agent. IFX (3-5 mg/kg at 0, 2, and 6 weeks and then every 4-8 weeks) was used in 75 cases and ADA (usually 40 mg every 2 weeks) in 50 cases. The main comparative outcome measures were improvement of visual acuity (VA) (at least 20%), complete inactivity of anterior chamber inflammation, vitritis, and retinal vasculitis as well as macular thickness <250 microns. A bivariate and logistic regression analysis was performed for every previous outcome between ADA vs IFX (SPSS20.0 package).

Results 125 patients (223 affected eyes) were studied. No statistically significant differences at baseline were observed between IFX vs ADA groups in sex (♂/♀; 41/34 vs 29/21; p=0,71), mean age (39,2±9.39 vs 36,14±12,7; p=0.12), HLA B51 positive (75% vs 75%), uveitis duration before anti TNF-α onset (median [IQR]; 36 [12-71] vs 24 months [12-60]; p=0.4), VA (0,47±0,26 vs 0,52±0,27; p=0,29), anterior chamber cells (median [IQR]; 0,5 [0-2] vs 1,5 [0-2]; p=0,2), retinal vasculitis (73,2% vs 75%; p=0,95); macular thickness (285,90±90,15 vs 312,02±106,57; p=0,25), combined treatment (82.7% vs 77,6%; p=0.481), basal degrees of immunosuppression (mean ± SD; 11.35±5.67 vs 9.65±4.68; p=0.09).

There were a better non-statistical respond with ADA in improvement of VA, complete inactivity of anterior chamber inflammation, and macular thickness <250 microns, and with IFX in inactivity of vitritis, and retinal vasculitis (Table)

Conclusions Our study suggests that ADA and IFX do not show statistical differences at one year in refractory uveitis of BD.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4766

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.